to this younger population, subject to obtaining regulatory approval,” as emphasized by Pfizer’s Chairman and CEO, Albert Bourla.
Therefore, the laboratories indicated that they planned to present these findings to the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory bodies “as soon as possible.” They also specified that they expected to obtain results in children under 5 years of age “by the end of the year.”
COVID-19 vaccine: Are children at greater risk with the delta variant
The question of vaccinating children under 12 is being raised, particularly due to the spread of coronavirus variants. “We are monitoring the spread of the Delta variant and the significant threat it poses to children,” stated Albert Bourla.
During August, US health professionals warned of a surge in hospitalizations due to the Delta variant in children. However, data released in early September by the US Centers for Disease Control and Prevention (CDC) revealed that while hospitalizations among children and adolescents had increased fivefold between late June and mid-August, the proportion of young people hospitalized for severe illness remained unchanged during the period when the Delta variant was predominant. The CDC also highlighted the effectiveness of the COVID-19 vaccine
